Litcius/Paper detail

Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Martin Dreyling, Jeanette K. Doorduijn, Eva Giné, Mats Jerkeman, Jan Walewski, Martin Hutchings, Ulrich Mey, Jon Riise, Marek Trněný, Vibeke Vergote, Melania Celli, Ofer Shpilberg, María Gomes da Silva, Sirpa Leppä, Linmiao Jiang, Christiane Pott, Wolfgang Hiddemann, Döndü Gözel, Christian Schmidt, Michael Unterhalt, Marco Ladetto, Eva Hoster

2022Blood84 citationsDOI

Topics & Concepts

Mantle cell lymphomaIbrutinibMedicineTransplantationRandomized controlled trialOncologySurgeryLymphomaInternal medicineLeukemiaChronic lymphocytic leukemiaLymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchT-cell and Retrovirus Studies
Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network | Litcius